Abstract
The management of coronary patients scheduled for a coronary artery bypass grafting (CABG), who are receiving one or more antiplatelet drugs, is plenty of controversies. It has been shown that withdrawal of antiplatelet drugs is associated with an increased risk of a thrombotic event, but surgery under an altered platelet function also means an increased risk of bleeding in the perioperative period. Because of the conflict recommendations, this review article tries to evaluate the outcome of different perioperative antiplatelet protocols in patients with coronary artery disease undergoing CABG.
Keywords: Cardiac Surgery, Antiplatelet-Drugs, Perioperative Management, coronary artery disease (CAD), coronary artery bypass grafting (CABG)
Related Books
Cardiac Resynchronization Therapy: An Established Pacing Therapy for Heart Failure and Mechanical Dyssynchrony
Cardiac Care and COVID-19: Perspectives in Medical Practice
4D Fetal Echocardiography
Frontiers in Myocardia
Frontiers in Myocardia
Frontiers in Myocardia
Latest Advances in Clinical and Pre-Clinical Cardiovascular MRI
Electrocardiography (ECG)
Degenerative Aortic Valve Disease, its Mechanism on Progression, its Effect on the Left Ventricle and the Postoperative Results
Focus Concise Animated Dictionary of Cardiology
4